Filing Flows › Nutex Health (NUTX) › Q2 2026
Nutex Health (NUTX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Nutex Health (NUTX) reported revenue of $211M for the second quarter 2026 (Q2 2026), -14% from a year earlier and -3% from the quarter before. Operating margin was 57.8%, net earnings $65.8M (31.2% of revenue).
Nutex Health, Q2 2026: revenue $211M (-14% year over year), operating margin 57.8%, net earnings $65.8M, operating cash flow $34.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $211M | -3% | -14% |
| Gross profit | $141M | +54% | +13% |
| Operating profit | $122M | +50% | +261% |
| Net earnings | $65.8M | +41% | — |
| Operating cash flow | $34.2M | -55% | +25% |
| Free cash flow | $31.7M | -57% | +19% |
What changed
Revenue was $210.8M in Q2 2026, down 14% year over year and down 3% from the previous quarter. Hospital division revenue was the largest line at 96% of revenue. Hospital division revenue lost $34.5M year over year (down 15%), 104% of the total change.
Gross margin was 67.0%, up 15.8 points from Q2 2025. Operating profit was $121.7M, a 57.8% margin (up 44.0 points year over year). Operating expenses fell 79% while revenue fell 14%. The fastest-growing cost line was General & admin (+33%). Net earnings were $65.8M. The effective tax rate was 17.7%.
Operating cash flow was $34.2M (up 25% year over year), 36% of net income including minority interests. Non-cash charges added back $5.3M of depreciation and amortization. Working capital and other items used $67.4M. Capital expenditures of $2.5M left free cash flow of $31.7M.
Questions
What was Nutex Health's revenue in the second quarter 2026?
Nutex Health (NUTX) reported revenue of $211M for the second quarter 2026 (Q2 2026), -14% from a year earlier and -3% from the quarter before.
Was Nutex Health profitable in the second quarter 2026?
Operating profit was $122M (57.8% of revenue) and net earnings $65.8M.
Source: Nutex Health 10-Q on SEC EDGAR.